Merck launches DTC campaign for Keytruda - MM+M - Medical Marketing and Media
Merck Hikes Forecast as Keytruda Tops $3 Billion for Quarter - Bloomberg
Merck's PD-1 Drug Outperforms Ipilimumab for Treatment of Advanced Melanoma - Cancer Research Institute
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Merck has high Keytruda hopes outside U.S., but Q1 details sparse | Fierce Pharma
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. firmnews.title_view.
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer | PharmiWeb.Jobs United States
KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement In Disease-Free Survival Versus Placebo As Adjuvant Treatment For Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless Of PD-L1 Expression 2023 - EORTC
F.D.A. Allows First Use of a Novel Cancer Drug - The New York Times
FDA Adcom Gives Merck's Keytruda a Surprise Thumbs Down | BioSpace
Merck & Co axes Keytruda lung cancer niche amid FDA crackdown | pharmaphorum
PRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced The Risk Of Distant Metastasis Or Death By 40% Compared Versus Placebo As Adjuvant Treatment In Resected, High-Risk Stage III Melanoma 2023 - EORTC
Hummingbird Bioscience collaborates with Merck for a clinical trial on HMBD-002, our anti-VISTA antibody, in combination with KEYTRUDA®
US FDA panel backs Merck & Co.'s Keytruda to treat type of bladder cancer | S&P Global Market Intelligence
Promega collaborate with Merck to develop MSI CDx for use with Keytruda
Asco 2018 – Merck's dominance leaves rivals scrabbling for subsets | Evaluate
ASCO: Can Keytruda expand further in first-line cervical cancer?
Pharma News | Merck, Sanofi, GSK, Hinova, Endogena, Amylyx
FDA Approves Merck's KEYTRUDA for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node | World Pharma Today
Merck's Keytruda Wins Approval for Yet Another Lung Cancer Indication | BioSpace
Merck, Moderna detail potential skin cancer vaccine progress | AP News
Merck & Co adds more Ph III data for Keytruda in stomach cancer
Drugmaker Merck tops 3Q forecasts as Keytruda sales jump 20% | AP News
Keytruda Approved by FDA for Further Potential Treatments of Mesothelioma | Mesothelioma Help Cancer Organization
FDA Accepts Application for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
